Genedata and Axxam collaborate on screening data analysis
Genedata and Axxam have signed a multi-year contract for the implementation of the Genedata Screener data analysis and management platform into Axxam’s high throughput screening process.
With an increasing number of pharma and life science companies outsourcing entire stages of their research cycle, the contributions of contract research organisations (CROs) to drug development is crucial. Faster development, earlier decisions on project failures, and higher approval success rates are becoming the norm. To continuously meet those high standards, Axxam relies on Genedata Screener. Screener’s high-quality, high-performance modular system rapidly and flexibly analyses, integrates and manages all assay data and then combines it with chemical, pharmacological and in vivo information to support Axxam scientists in prioritising compounds and identifying quality lead structures with the highest confidence. Screener's open and scalable architecture integrates with existing infrastructures, which allows it to be tailored to specific discovery processes, maximising its value.